Document is current

Article History

Received: 10 February 2025

Accepted: 21 May 2025

First Online: 15 July 2025

Declarations

:

: R. Bütof, L. Koi, S. Löck, S. Appold, S. Drewes, D. Koschel, J. Kotzerke, U. Nestle, S. Adebahr, D. Zips, F. Heinzelmann, T. Hehr, D. Bucher, J. Heide, C. Belka, F. Manapov, E. Wasilewska-Tesluk, J. Fleckenstein, M. Krause, E.G.C. Troost, and M. Baumann declare that they have no competing interests. M. Baumann, CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg, Germany), is responsible for collaborations with many companies and institutions worldwide. In this capacity, he has signed contracts for research funding and/or collaborations, including commercial transfers, with industry and academia on behalf of his institute(s) and staff. He is a member of several supervisory boards, advisory boards, and boards of trustees. Michael Baumann confirms that he has no conflict of interest with respect to this paper. F. Manapov received an unrestricted research institutional grant from AstraZeneca and honoraria from AstraZeneca, Novartis, Roche, Lilly, Elekta, and Brainlab. He serves on the advisory boards of AstraZeneca and Novartis. Farkhad Manapov confirms that he has no conflict of interest with respect to this paper.

: All procedures were performed in compliance with relevant laws and institutional guidelines, and the study was approved in 2014 by the ethics committee of the TUD Dresden, University of Technology, EK149042014. Each patient has given their written informed consent to participate in the study.ClinicalTrials.gov: NCT02189967